Search This Blog

Thursday, October 9, 2025

Big banks are walking a political tightrope in Trump's Washington

 The country’s largest banks are navigating a delicate balancing act in President Trump's Washington.

CEOs for some of the biggest US lenders, including JPMorgan Chase (JPM), Goldman Sachs (GS), Bank of America (BAC), Citigroup (C), Morgan Stanley (MS), and Wells Fargo (WFC), are all competing to win a leading role in a lucrative public offering for mortgage giants Fannie Mae and Freddie Mac, a competition that has involved Oval Office appearances with the president.

At the same time, Trump has called out some of these same Wall Street bosses over "debanking." Some are now facing increasing scrutiny from their regulators over whether they denied or refused services to conservative customers. Their legal and regulatory affairs teams are currently combing through old records for any account closures.

"There are a lot of areas where we're playing offense," said Greg Baer, CEO of the Bank Policy Institute, an industry trade group. "There's some areas where we're playing defense. It makes for a very complicated battlefield, that's for sure."

Banks began the Trump administration with high hopes for broad, sweeping reforms that would work to their advantage.

And that does appear to be happening. Bank regulators are proposing the biggest walk-back in rules since Congress tightened the reins on the industry following the 2008 financial crisis with a piece of legislation known as Dodd-Frank.

The Fed, for example, has unveiled proposals to relax key bank capital components based on leverage and its annual stress-test exercise specific to large banks. It will host a conference on Thursday designed to air concerns about the regulation of smaller community banks.

"It's 15 years later, right, since Dodd-Frank was originally envisioned," Michelle Bowman, the Federal Reserve's top banking supervisor, said during a Georgetown University event in late September.

"I think we have a good perspective on what's been working, what could be improved," Bowman added.

But the Trump administration has also made things more complicated for banks at the same time.

For one, it has provided regulatory relief to the crypto industry, which is emerging as an upstart competitor to banks within the financial world. Some crypto companies are now seeking banking licenses — a sign they intend to push deeper onto banks' turf.

Bank lobbyists are pushing back. They're seeking language to bar non-bank crypto platforms from offering interest payments on customer stablecoin balances in a forthcoming crypto market structure bill, arguing that doling out interest on stablecoins creates less-regulated "pseudo-banks."

"Everybody would want to be in the business of issuing money and offering something that's a money-like instrument without being subject to the same level of oversight," BPI's Baer said on the subject.

"That would be an incredibly profitable business," Baer added.

Major crypto platform Coinbase (COIN), which offers financial "rewards" on stablecoin holdings, has already urged customers to oppose big banks on the issue.

Another challenge for banks trying to navigate the new administration is the focus on debanking, which Trump highlighted in January when he confronted Bank of America CEO Brian Moynihan at the World Economic Forum in Davos, Switzerland. In August, he signed an executive order on the issue.

Last month, the Office of the Comptroller of the Currency said it had requested information about debanking activities from nine of the largest institutions it regulates. The review is scheduled to be completed early next year.

Some of those same institutions that received letters anticipate negotiations with the administration and potentially lawsuits to follow, according to one source familiar with the matter.

Smaller banks also received debanking letters in September, according to the Wall Street Journal.

The Small Business Administration wrote to 5,000 banks and other lenders directing them to make reasonable efforts by Dec. 5 to find customers they previously cut off for political or debanking reasons, according to the Wall Street Journal.

Banks have denied discriminating against Trump and other customers based on their political or religious affiliations. However, they have also said their decision to shut down accounts or turn away potential customers is based on financial and legal risks, which banks are held accountable for by regulators.

The president has said that both JPMorgan Chase and Capital One (COF) closed family and business accounts after he left the White House in 2021, while Bank of America refused to offer him services.

"The banks discriminated against me very badly, and I was very good to the banks," Trump said on CNBC's "Squawk Box" in August.

https://finance.yahoo.com/news/big-banks-are-walking-a-political-tightrope-in-trumps-washington-090027516.html

Bluejay, SanyoSeiko Expand Partnership to Advance Commercialization of Symphony Platform



Bluejay Diagnostics (NASDAQ: BJDX) and SanyoSeiko agreed on Oct. 9, 2025 to amend their Master Service Agreement and Master Supply Agreement to expand SanyoSeiko’s role in commercializing the Symphony near-patient testing platform.

Under statements of work already provided, SanyoSeiko will provide end-to-end support including manufacturing redevelopment for analyzers and cartridges, hardware/software/design updates, raw material sourcing, vendor compliance, kit assembly, labeling, packaging, shipping, quality control, regulatory and quality management support, and equipment storage and maintenance. The companies say the amended agreements aim to strengthen supply chain resilience, secure production capacity, and advance readiness for broader clinical validation and market introduction.

Turn Therapeutics to Commence Trading Today on Nasdaq

 Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces that its common stock is scheduled to commence trading today, October 8, 2025, on the Nasdaq Capital Market under ticker symbol “TTRX.” 

The Company’s registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission (“SEC”) September 30, 2025. Clear Street LLC served as financial advisor to the company. Davis, Polk, and Wardwell acted as legal counsel. 

To mark the occasion, Turn Therapeutics will participate in a Closing Bell Ceremony at 4:00 PM Eastern Time on October 8, 2025, which will be broadcast live from Nasdaq’s MarketSite in New York. 

Watch the ceremony live at 4pm ET via the following link: https://www.nasdaq.com/marketsite/bell-ringing-ceremony

About Turn Therapeutics
Turn Therapeutics is a biotechnology company developing and commercializing products for dermatology, wound care, and infectious disease. The company has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. In addition, Turn is pursuing global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide, reflecting its commitment to public health innovation.

https://www.globenewswire.com/news-release/2025/10/08/3163290/0/en/Turn-Therapeutics-to-Commence-Trading-Today-on-Nasdaq.html

Wednesday, October 8, 2025

Nearly Three Quarters of FDA Breakthrough Designated Drugs Win Approval: Report

 

New analysis from Jefferies shows that rare disease and cancer drugs granted the status are especially likely to be approved.

Around 72% of drugs given the FDA’s breakthrough therapy designation between 2013 and 2022 went on to win approval, with another 13% still awaiting a decision, according to a recently released report from Jefferies.

Jefferies’ report includes a new analysis of 599 breakthrough therapy designations (BTDs)—intended to expedite drugs targeted at serious conditions—from 2013 to 2025 (YTD) that “provides another pot’l proofpoint that the ‘new FDA’ remains functional,” the analysts wrote on Sunday, though other commentors noted the FDA might be just operating from a place of confirmation bias.

Using data from the FDA, Friends of Cancer Research and Biomedtracker, Jefferies broke the breakthrough approvals down into sectors, showing that many were granted for oncology indications. Cancer drugs made up 176 of the 223 drugs that were approved after receiving breakthrough designation for the decade covered. This makes mathematical sense, as oncology therapies accounted for 46% of all breakthrough designations between 2013 to 2025 (275 out of 599 total), trailed by drugs for infectious diseases (11%), metabolic diseases (8%) and neurological diseases (7%). Therapies for rare diseases across indications, including oncology, accounted for the majority of all designations, at 383 out of 599 total breakthrough designations granted between 2013 and 2025.

“On its face—you can’t tell whether the learning is that FDA has a keen ability to identify the most promising drugs relatively early in the process . . . or whether FDA pushes those drugs forward (in largely unconscious fashion) in a form of confirmation bias,” Steven Grossman, a policy analyst and expert who writes the FDA Matters blog, told BioSpace in an email. Grossman suggested that it could be some of both.

Of the therapies that didn’t make it across the finish line, 43% (30 of 69 failed breakthrough-designated drugs) were thwarted during clinical studies. Rare diseases were the most successful even within the failures, with only 13% of these assets discontinued during the study period.

Breakthrough designations are only one of several tools the FDA is leveraging to expedite drugs for high unmet needs to the market. Others introduced just this year include the Commissioner’s National Priority Voucher (CNPV) program, announced in June, and the Rare Disease Evidence Principles (RDEP) review process for rare diseases, rolled out last month.

But designations and vouchers, like the CNPV, serve different needs, Grossman said.

“Designations get you more FDA attention and a shot at a faster process long before, as well as during, the NDA review. You don’t get a designation until there is something defined and ‘there,’” he explained.

“Vouchers are really to incentivize projects with higher risk that are in danger of never happening (never reaching a stage where they would be eligible to be designated). In practice, they get mixed together because you (and your investors) are going to be looking for every confirmation from FDA that they are going to be supportive, pending scientific results.”

Jefferies has consistently taken a positive stance on the state of the “new FDA” that has formed under the leadership of Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary. In August, the analyst firm published data that showed the regulator is roughly on track to approve a similar number of novel drugs as in the past five years.

“We remain (+) on the state of the FDA, even after Dr. Peter Marks’ CBER resignation (March 2025) and Dr. Vinay Prasad’s subsequent appointment (May 2025), departure (July 2025), and return (Aug 2025),” the analysts wrote in their Sunday note to investors. The agency’s activity in advisory committees, other approvals and desire to release complete response letters for rejected therapies leads the analysts to believe the regulatory environment at the FDA “has not worsened” compared to prior years, they wrote.

https://www.biospace.com/fda/nearly-three-quarters-of-fda-breakthrough-designated-drugs-win-approval-report

Merz to host German auto sector crisis meeting

 German Chancellor Friedrich Merz will meet with auto sector representatives, including suppliers, manufacturers, state officials, and trade unions, in Berlin on Thursday to address the severe downturn in one of the flagship sectors of the country.

Finding cooperative solutions to successfully prepare the automotive industry for future technologies will be the main goal of the two-hour meeting, according to the German government.

After the meeting, updates will be given by Merz, Finance Minister Lars Klingbeil, German Association of the Automotive Industry (VDA) President Hildegard Müller, and IG Metall union chairperson Christiane Benner.

https://breakingthenews.net/Article/Merz-to-host-German-auto-sector-crisis-meeting/64950853

U.S. sanctions 29 companies in China, Turkey, and UAE over Iran military support

 The sanctions target companies in China (15 firms), Turkey, and the UAE, which the U.S. accuses of providing illicit support to Iran's military

https://seekingalpha.com/news/4502838-us-sanctions-29-companies-in-china-turkey-and-uae-over-iran-military-support

China Widens Rare Earth Curbs Ahead of Critical Xi-Trump Meeting

 


China has tightened curbs on rare earths to include items manufactured abroad, adding a potentially complex layer of restrictions to an industry that’s been a source of intense trade friction between Beijing and Washington.

Overseas exporters of items that use certain rare earths sourced from China will need to obtain an export license from the country’s Ministry of Commerce, according to statements from the ministry on Thursday, which cited the need to protect China’s national security and interests.

https://www.bloomberg.com/news/articles/2025-10-09/china-tightens-exports-of-rare-earths-and-related-technology